New approaches in treatment of gout: febuxostat


V.V. Tseltsov, A.I. Martynov, Yu. Sh. Guschina, T.S. Illarionova, E.A. Koroviakova

1 State Unitary Institution “Mayor and Moscow City Government administrarion Medical Center”, Moscow
Efficacy and safety of new non-purine inhibitor of xantine-oxidase – febuxostat – are described. Results of pharmacocinetic and clinical trials, results of comparison with allopurinol in patients with hyperuricemia and gout are reviewed.

About the Autors


Tseltsov V.V. – professor, head specialist at State Unitary Institution “Mayor and Moscow City Government administrarion Medical Center”, Ph.D.
E-mail: vcheltsov@mail.ru;
Martynov A.I.- general director of State Unitary Institution “Mayor and Moscow City Government administrarion Medical Center”, academician of Russian Academy of Medical Sciences;

Guschina Yu. Sh. – associate professor at Department of common and clinical pharmacology at Federal State Budgetary Educational Institution if High Professional Education Peoples’ Friendship University Ministry of Education and Science of Russia;

Illarionova T.S. - associate professor at Department of common and clinical pharmacology at Federal State Budgetary Educational Institution if High Professional Education Peoples’ Friendship University Ministry of Education and Science of Russia;

Koroviakova E.A. - associate professor at Department of common and clinical pharmacology at Federal State Budgetary Educational Institution if High Professional Education Peoples’ Friendship University Ministry of Education and Science of Russia.


Similar Articles


Бионика Медиа